Molecular Historical Financial Ratios
| MTEM Stock | USD 0.40 0.06 17.65% |
Molecular Templates is lately reporting on over 115 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 1.74 will help investors to properly organize and evaluate Molecular Templates financial condition quickly.
Molecular |
About Molecular Financial Ratios Analysis
Molecular TemplatesFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Molecular Templates investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Molecular financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Molecular Templates history.
Molecular Templates Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Molecular Templates stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Molecular Templates sales, a figure that is much harder to manipulate than other Molecular Templates multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Molecular Templates dividend as a percentage of Molecular Templates stock price. Molecular Templates dividend yield is a measure of Molecular Templates stock productivity, which can be interpreted as interest rate earned on an Molecular Templates investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Stock Based Compensation To Revenue
A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Most ratios from Molecular Templates' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Molecular Templates current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Templates. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Molecular Stock, please use our How to Invest in Molecular Templates guide.At this time, Molecular Templates' Net Debt To EBITDA is very stable compared to the past year. As of the 26th of November 2024, Tangible Book Value Per Share is likely to grow to 0.84, while Days Sales Outstanding is likely to drop 1.74.
| 2023 | 2024 (projected) | Dividend Yield | 0.007547 | 0.006709 | Price To Sales Ratio | 0.29 | 0.28 |
Molecular Templates fundamentals Correlations
Click cells to compare fundamentals
Molecular Templates Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Molecular Templates fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 27.1 | 28.59 | 5.6 | 0.94 | 0.29 | 0.28 | |
| Ptb Ratio | 5.13 | 7.53 | 3.3 | (1.23) | 3.99 | 4.19 | |
| Book Value Per Share | 40.92 | 18.7 | 17.81 | (4.03) | 0.94 | 0.98 | |
| Free Cash Flow Yield | (0.066) | (0.2) | (0.16) | (4.96) | (2.5) | (2.38) | |
| Operating Cash Flow Per Share | (10.03) | (26.4) | (8.24) | (23.7) | (9.29) | (9.76) | |
| Stock Based Compensation To Revenue | 0.3 | 0.76 | 0.43 | 0.6 | 0.12 | 0.11 | |
| Capex To Depreciation | 8.16 | 1.89 | 0.6 | 0.43 | 0.0301 | 0.0286 | |
| Pb Ratio | 5.13 | 7.53 | 3.3 | (1.23) | 3.99 | 4.19 | |
| Ev To Sales | 23.47 | 28.71 | 6.12 | 1.87 | 0.31 | 0.29 | |
| Free Cash Flow Per Share | (13.86) | (28.73) | (9.33) | (24.56) | (9.34) | (9.8) | |
| Roic | (0.66) | (1.36) | (0.76) | (4.23) | (2.48) | (2.36) | |
| Net Income Per Share | (27.62) | (33.06) | (21.51) | (24.69) | (1.8) | (1.9) | |
| Payables Turnover | 34.48 | 39.56 | 4.16 | 15.48 | 4.54 | 4.31 | |
| Sales General And Administrative To Revenue | 1.03 | 1.71 | 0.88 | 1.33 | 0.33 | 0.31 | |
| Research And Ddevelopement To Revenue | 2.59 | 5.95 | 2.19 | 4.17 | 0.85 | 0.81 | |
| Capex To Revenue | 0.49 | 0.47 | 0.1 | 0.16 | 0.00349 | 0.003316 | |
| Cash Per Share | 49.68 | 29.58 | 38.8 | 16.26 | 2.56 | 2.43 | |
| Pocfratio | (20.93) | (5.33) | (7.13) | (0.21) | (0.4) | (0.42) | |
| Interest Coverage | (54.28) | (59.14) | (23.77) | (18.58) | (3.94) | (4.14) | |
| Capex To Operating Cash Flow | (0.38) | (0.0882) | (0.13) | (0.0359) | (0.004782) | (0.005022) | |
| Pfcf Ratio | (15.14) | (4.9) | (6.3) | (0.2) | (0.4) | (0.42) | |
| Days Payables Outstanding | 10.58 | 9.23 | 87.82 | 23.58 | 80.44 | 148.83 | |
| Income Quality | 0.36 | 0.8 | 0.37 | 0.96 | 5.15 | 5.41 | |
| Ev To Operating Cash Flow | (7.87) | (18.13) | (5.36) | (7.79) | (0.42) | (0.44) | |
| Pe Ratio | (7.6) | (4.26) | (2.73) | (0.2) | (2.07) | (2.17) | |
| Return On Tangible Assets | (0.4) | (0.76) | (0.41) | (0.96) | (0.23) | (0.25) | |
| Ev To Free Cash Flow | (13.11) | (4.92) | (6.89) | (0.4) | (0.42) | (0.44) | |
| Earnings Yield | (0.13) | (0.23) | (0.37) | (4.99) | (0.48) | (0.51) | |
| Intangibles To Total Assets | 0.007463 | 0.008579 | 0.005718 | 0.007176 | 0.017 | 0.0161 | |
| Net Debt To E B I T D A | 1.07 | (0.0194) | (0.28) | (0.23) | 0.49 | 0.98 | |
| Current Ratio | 3.23 | 3.91 | 2.7 | 1.2 | 0.97 | 0.92 | |
| Tangible Book Value Per Share | 40.4 | 18.32 | 17.51 | (4.22) | 0.8 | 0.84 | |
| Graham Number | 159.45 | 117.93 | 92.86 | 47.31 | 6.16 | 5.86 | |
| Shareholders Equity Per Share | 40.92 | 18.7 | 17.81 | (4.03) | 0.94 | 0.98 | |
| Debt To Equity | 0.0363 | 0.25 | 0.54 | (2.39) | (2.75) | (2.61) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Templates. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Molecular Stock, please use our How to Invest in Molecular Templates guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Templates. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Templates listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.97) | Earnings Share (3.05) | Revenue Per Share 4.544 | Quarterly Revenue Growth (0.92) | Return On Assets (0.38) |
The market value of Molecular Templates is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Templates' value that differs from its market value or its book value, called intrinsic value, which is Molecular Templates' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Templates' market value can be influenced by many factors that don't directly affect Molecular Templates' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Templates' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Templates is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Templates' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.